BOLD - CIK 0001782303
The table below shows Boundless Bio, Inc.'s cash flow statement by quarter, as reported in the company's quarterly filings. All figures are in US dollars; negative values appear in red.
| Line item | Q1 2026 | Q1 2025 | Q1 2024 | Q1 2023 |
|---|---|---|---|---|
| Operating cash flow | -$14.97M | -$14.53M | -$15.78M | -$12.09M |
| Capital expenditure | $8.00K | $59.00K | $83.00K | $86.00K |
| Investing cash flow | $14.59M | $3.06M | $18.14M | $22.17M |
| Dividends paid | - | - | - | - |
| Stock buybacks | - | - | - | - |
| Financing cash flow | - | - |
Boundless Bio, Inc. reported operating cash flow of -$46.66M for fiscal year 2025. That is up 23.3% from -$60.84M in fiscal 2024. Figures come from the company's audited annual reports as filed with the SEC.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
| -$924.00K |
| $31.00K |